Objective: To study cyclinD1/bcl-1 and p27/kip1 expression in gliomas and their correlation with pathological grade and prognosis. Methods: Immunohistochemical technique was used to detect the cyclinDl/bcl-1 andp27/ki...Objective: To study cyclinD1/bcl-1 and p27/kip1 expression in gliomas and their correlation with pathological grade and prognosis. Methods: Immunohistochemical technique was used to detect the cyclinDl/bcl-1 andp27/kip1 expression in 48 human brain glioma tissues of different malignant grades, and 12 normal non.neoplastic tissues collected from internal decompression. The data were analyzed quantitatively by the image system and also correlated retrospectively with the patients' clinical characteristics. Results: The immunohistochemical reaction for cyclinD1/bcl.1 and p27/kip1 was confined to the nuclei. The abnormal positive expression rates of both cyclinD1/bcl-1 and p27/kip1 in gliomas were found higher than that in non-neoplastic tissues(P<0.05). The number and staining intensity of cyclinD1/bel-1 positive nuclei increased with malignant grades (P<0.05). On the contrary, the positive nuclei of p27/kip1 expression decreased in number and staining intensity with malignant grades( P < 0.05). Higher expressionof cyclinD1/bel-1 or/and lower expression of p27/kip1 were associated with poor prognosis( P < 0.05). Conclusion: The abnormal expression of both cyclinD1/bel-1 and p27/kip1 might be closely related to the occurrence and development of gliomas and they might have synergistic effect. These data suggest that both cyclinDl/bel-1 expression and p27/kip1 expression can act as an independent prognostic factor.展开更多
The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct mol...The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase(MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor(EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice.展开更多
文摘Objective: To study cyclinD1/bcl-1 and p27/kip1 expression in gliomas and their correlation with pathological grade and prognosis. Methods: Immunohistochemical technique was used to detect the cyclinDl/bcl-1 andp27/kip1 expression in 48 human brain glioma tissues of different malignant grades, and 12 normal non.neoplastic tissues collected from internal decompression. The data were analyzed quantitatively by the image system and also correlated retrospectively with the patients' clinical characteristics. Results: The immunohistochemical reaction for cyclinD1/bcl.1 and p27/kip1 was confined to the nuclei. The abnormal positive expression rates of both cyclinD1/bcl-1 and p27/kip1 in gliomas were found higher than that in non-neoplastic tissues(P<0.05). The number and staining intensity of cyclinD1/bel-1 positive nuclei increased with malignant grades (P<0.05). On the contrary, the positive nuclei of p27/kip1 expression decreased in number and staining intensity with malignant grades( P < 0.05). Higher expressionof cyclinD1/bel-1 or/and lower expression of p27/kip1 were associated with poor prognosis( P < 0.05). Conclusion: The abnormal expression of both cyclinD1/bel-1 and p27/kip1 might be closely related to the occurrence and development of gliomas and they might have synergistic effect. These data suggest that both cyclinDl/bel-1 expression and p27/kip1 expression can act as an independent prognostic factor.
文摘The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase(MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor(EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice.
